Nine months report ended January 2003

Nine months report ended January 2003 - Operating profit improved sharply, by SEK 102 M, to SEK 235 M (133) and the operating margin rose to 12 (7) percent. - Cash flow after investments was positive, amounting to SEK 180 M (neg: 61). - Order bookings increased by 7 percent to SEK 2,212 M (2,076). - Net sales increased by 6 percent to SEK 2,037 M (1,913). - Net sales of after-market products and services in-creased by 11 percent, to SEK 605 M (545), and ac-counted for 30 (28) percent of the Group total. - Earnings per share after dilution improved by 60 per-cent to SEK 4.82 (3.00). For additional information, please contact: Lars Jonsteg, Vice President, Corporate Communications, Elekta AB (publ) tel. +46-8-587 254 82 or +46-708-78 37 35 Additional information is available at: ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report

About Us

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm.


Documents & Links